Abstract:ID 90311 Poster Board 475 The D 2 dopamine receptor (D2R) is a G protein-coupled receptor (GPCR) and a validated drug target for the treatment of many neuropsychiatric disorders, including psychosis. All currently available antipsychotics are antagonists of the D2R; however, all of these drugs exhibit polypharmacology resulting in a plethora of off-target side effects including weight gain, dysphoria, and sedation, among others. A highly-selective D2R antagonist might overcome these pitfalls and increase patient compliance with taking antipsychotic medications. Previously, our lab conducted a high-throughput screen to identify D2R-selective antagonists with reduced activity at other GPCRs. This screen identified a promising hit compound that was chemically optimized into the lead drug candidates, NCGC1360 and NCGC1366. These drug leads have relatively high binding affinities at the D2R (~80 and ~50 nM, respectively), while displaying >100-fold selectivity over the D3R and >24-fold selectivity over the D4R. A β-arrestin recruitment assay revealed even higher D2R selectivity (>100-fold) of these compounds over the D3R and D4R. In a screen against an array of 46 GPCRs, channels, and transporters using radioligand binding assays, NCGC1360 and NCGC1366 only inhibited radioligand binding to the D2R. A functional screen of 168 GPCRs further determined that NCGC1360 and NCGC1366 were exceptionally selective with each compound completely antagonizing β-arrestin recruitment to the D2R with only minor effects at a few other receptors. Schild-type analyses using dopamine-stimulated β-arrestin recruitment revealed that both compounds are competitive antagonists. A comparative molecular docking study using the active structures of both the D2R and D3R showed that NCGC1366 occupies the orthosteric binding pocket of the D2R with extended contacts with residues in extracellular loop 2 (ECL2). The contacts in ECL2 are not conserved between the D2R and D3R, which may confer D2R selectivity. We thus swapped the ECL2 of the D2R and D3R and found that a D2R mutant with the D3R ECL2 exhibited diminished affinity for NCGC1360 and NCGC1366. Conversely, a D3R mutant with the D2R ECL2 exhibited increased affinity for NCGC1360 and NCGC1366, consistent with the molecular docking study. Pharmacokinetic studies of NCGC1360 in mice revealed a half-life of 1.8 hr in plasma and 1 hr in brain with excellent brain penetration. Finally, NCGC1360 was characterized in animal models that are predicative of antipsychotic efficacy and on-target side effects. NCGC1360 dose-dependently decreased amphetamine-induced hyperlocomotion in mice and also rescued deficits in pre-pulse inhibition induced by amphetamine. Importantly, NCGC1360 did not induce catalepsy up to the highest dose tested (10 mg/kg), suggesting that it would not induce extrapyramidal side effects in patients. Taken together, these studies provide support for continuing the development of this scaffold with preclinical and IND-enabling studies. Funded by the National Institutes of Health intramural research program.

Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia

In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia

A Novel Dual Serotonin Transporter and M-channel Inhibitor D01 for Antidepression and Cognitive Improvement

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action

Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

Identification of N-phenyl-3-methoxy-4-pyridinones As Orally Bioavailable H3 Receptor Antagonists and Β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease.

Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation

Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling

In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis

Novel α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor (AMPAR) potentiator LT‐102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia

Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/H3 Agents: Synthesis and Biological Evaluation

Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Characterization of NCGC1360 and NCGC1366 as Highly-Selective D2 Dopamine Receptor Antagonists and Lead Candidates for the Treatment of Neuropsychiatric Disorders

Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor

The antidepressant-like effect and proposed mechanism of action of TPN672MA, a novel serotonin-dopamine receptor modulator for the treatment of schizophrenia

Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics

Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models